Roche raised the curtain on its novel approach to DNA sequencing earlier this year, and now it's working with the Broad ...

Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently ...

Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair ...

With Illumina currently banned from shipping its DNA sequencers into China—in retaliation for the Trump administration’s ...

Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

Moderna filed for FDA approval of its mRNA-1083 combination shot last year. The submission put the biotech on track to win ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Innate Pharma has claimed long-term data from a phase 2 study show that its anti-KIR3DL2 antibody has a “sustained effect” ...

Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum ...

Medtronic plans to separate from its diabetes business and launch it as an independent company—one that will count more than ...

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has ...